VY7523 + Placebo Comparator

Phase 1/2Active

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer's Disease (AD)

Conditions

Alzheimer's Disease (AD)

Trial Timeline

Mar 3, 2025 → May 1, 2027

NCT ID

NCT06874621

About VY7523 + Placebo Comparator

VY7523 + Placebo Comparator is a phase 1/2 stage product being developed by Voyager Therapeutics for Alzheimer's Disease (AD). The current trial status is active. This product is registered under clinical trial identifier NCT06874621. Target conditions include Alzheimer's Disease (AD).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06874621	Phase 1/2	Active	Mar 3, 2025	May 1, 2027	Alzheimer's Disease (AD)

Competing Products

1 competing product in Alzheimer's Disease (AD)

See all competitors

Product	Company	Stage	Hype Score
Lecanemab treatment group + Conventional anti-dementia treatment group	Eisai	Pre-clinical	23